Company intelligence / Profile preview

Nové al

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Nové is a generative AI biotechnology company focused on the de novo design of novel proteins and programmable medicines. Founded by leading researchers from the Institute for Protein Design and Duke University, the company leverages advanced machine learning models to engineer therapeutics with high precision and optimized pharmacological properties. Their platform integrates computational design with high-throughput experimental validation to address challenging and "undruggable" biological targets. Nové aims to transition drug discovery from traditional screening methods to a predictive, engineering-based approach.

Therapeutic areas: Other
Modalities: ProteinPeptideSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Nové al.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nové al.

Explore the full profile